Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $5.3 million.

  • Ani Pharmaceuticals' Gains from Investment Securities was N/A to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year change of. This contributed to the annual value of $5.3 million for FY2024, which is 13.40% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Gains from Investment Securities is $5.3 million, which was up 13.40% from $4.7 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Gains from Investment Securities peaked at $5.3 million during FY2024, and registered a low of $1.6 million during FY2020.
  • In the last 2 years, Ani Pharmaceuticals' Gains from Investment Securities had a median value of $5.0 million in 2023 and averaged $5.0 million.
  • Data for Ani Pharmaceuticals' Gains from Investment Securities shows a peak YoY skyrocketed of 1,211.48% (in 2020) over the last 5 years.
  • Yearly analysis of 3 years shows Ani Pharmaceuticals' Gains from Investment Securities stood at $1.6 million in 2020, then reached $4.7 million in 2023, then grew by 13.40% to $5.3 million in 2024.